Journal
BIOMARKER RESEARCH
Volume 8, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40364-020-00222-3
Keywords
Chronic lymphocytic leukemia; Prognosis; Prognostic biomarkers; Risk scoring systems
Categories
Funding
- National Natural Science Foundation [81270598, 81473486, 81770210]
- Key Research and Development Program of Shandong Province [2018CXGC1213]
- Technology Development Projects of Shandong Province [2017GSF18189]
- Taishan Scholars Program of Shandong Province
- Shandong Provincial Engineering Research Center of Lymphoma
- Key Laboratory for Kidney Regeneration of Shandong Province
- Academic promotion programme of Shandong First Medical University
- Shandong Provincial Hospital Youth Talent Plan
- Shandong Provincial Hospital Research Incubation Fund
Ask authors/readers for more resources
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation status, microRNAs, chromosome aberrations and gene mutations, have contributed to prognosis in CLL. Del17p/ TP53 mutation, NOTCH1 mutation, CD49d, IGHV mutation status, complex karyotypes and microRNAs were reported to be of predictive values to guide clinical decisions. Based on the biomarkers above, classic prognostic models, such as the Rai and Binet staging systems, MDACC nomogram, GCLLSG model and CLL-IPI, were developed to improve risk stratification and tailor treatment intensity. Considering the presence of novel agents, many investigators validated the conventional prognostic biomarkers in the setting of novel agents and only TP53 mutation status/del 17p and CD49d expression were reported to be of prognostic value. Whether other prognostic indicators and models can be used in the context of novel agents, further studies are required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available